Table 2 Demographics, medications and disease activity in AM and non-AM patients
Clinical features | AM*(N = 11) | Non AM (N = 17) | p value |
|---|---|---|---|
| Â | Median (range) | Median (range) | Â |
Age (years) | 52 (36 to 63) | 50 (20 to 63) | 0.56 |
Duration of PsA (years) | 12 (5 to 35) | 10 (5 to 25) | 0.51 |
Duration of psoriasis (years) | 22 (11 to 49) | 20 (5 to 50) | 0.24 |
Weight (kg) mean (range) | 78 (65 to 107) | 83 (68 to 111) | 0.42 |
Female:Male | 3:8 | 8:9 | 0.44 |
Ethnicity: European | 91% | 88% | 0.94 |
Medications | Number (%) | Number (%) | Â |
Methotrexate | 4 (36%) | 11 (65%) | Â |
NSAIDs | 7 (64%) | 10 (10%) | Â |
Prednisone 5 to 20 mg/day | 2 (18%) | 2 (12%) | Â |
Sulphasalazine 2 to 3 g/day | 3 (28%) | 5 (29%) | Â |
Azathioprine 150 mg/day | 0 | 1 (6%) | Â |
Hydroxychloroquine 400 mg/day | 0 | 1 (6%) | Â |
Leflunomide 20 mg/day | 1 (9%) | 0 | Â |
Cyclosporin 100 mg/day | 0 | 1 (6%) | Â |
Disease activity | Median (range) | Median (range) | Â |
Tender joint count | 17 (1 to 40) | 11 (4 to 51) | 0.98 |
Swollen joint count | 6 (0 to 33) | 4 (0 to 9) | 0.20 |
Pain score | 35 (16 to 78) | 45 (6 to 82) | 0.47 |
HAQ score (n = 27) | 1.1 (0 to 3.5) | 0.7 (0 to 3) | 0.26 |
PF-SF-36 | 52.5 (5 to 85) | 65 (10 to 90) | 0.39 |
ESR (mm/hour) | 14 (1 to 43) | 13 (2 to 86) | 0.61 |
CRP (mg/litre) (n = 25) | 11.6 (3 to 59) | 4.9 (< 1 to 46) | 0.26 |
DAS28-CRP (n = 23) | 3.91 (2.6 to 5.7) | 4.2 (2.3 to 6.2) | 0.64 |
DAS28-ESR (n = 28) | 4.2 (1.7 to 6.1) | 4.0 (1.9 to 6.9) | 0.61 |
Psoriatic nail severity score | 11 (0 to 47) | 8 (0 to 22) | 0.19 |
PASI (n = 26) | 0.6 (0 to 12) | 1.8 (0 to 10.3) | 0.84 |